Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

References

• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428.e2. doi:10.1016/j.anai.2020.12.020
   PubMed Web of Science ®Google Scholar
• Mastorino L, Viola R, Panzone M, et al. Dupilumab induces a rapid decrease of pruritus in adolescents: a pilot real-life study. Dermatol Ther. 2021;34(6):e15115. doi:10.1111/dth.15115
   PubMed Web of Science ®Google Scholar
• Miniotti M, Ribero S, Mastorino L, et al. Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: data up to 3 years. Exp Dermatol. 2023;32(6):852–858. doi:10.1111/exd.14786
   PubMed Web of Science ®Google Scholar
• Barbarot S, Silverberg JI, Gadkari A, et al. The Family Impact of Atopic Dermatitis in the Pediatric Population: results from an International Cross-sectional Study. J Pediatr. 2022;246:220–226.e5. doi:10.1016/j.jpeds.2022.04.027
   PubMed Web of Science ®Google Scholar
• Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–682. doi:10.1016/j.jaad.2019.08.032
   PubMed Web of Science ®Google Scholar
• McKenzie PL, Castelo-Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis. J Am Acad Dermatol. 2021;84(6):1691–1694. doi:10.1016/j.jaad.2021.01.046
   PubMed Web of Science ®Google Scholar
• Sun R, Kong D. Bilateral Association Between Atopic Dermatitis and Alopecia Areata: a Systematic Review and Meta-Analysis. Dermatitis. 2023. doi:10.1089/derm.2023.0114
   Google Scholar
• Chen W, Li S, Cai X, et al. Association between alopecia areata and atopic dermatitis: current evidence. J Eur Acad Dermatol Venereol. 2023;13:44. doi:10.1111/jdv.19044
   Google Scholar
• Kageyama R, Ito T, Hanai S, et al. Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata. Int J Mol Sci. 2021;22(5):2618.
   PubMed Web of Science ®Google Scholar
• Muddebihal A, Khurana A, Sardana K. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. Expert Rev Clin Pharmacol. 2023;16(4):279–295. doi:10.1080/17512433.2023.2193682
   PubMed Web of Science ®Google Scholar
• Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;36(8):1292–1299. doi:10.1111/jdv.18141
   PubMed Web of Science ®Google Scholar
• Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: the Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023;159(6):596–605. doi:10.1001/jamadermatol.2023.0627
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi:10.1056/NEJMoa2206714
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi:10.1016/s0140-6736(20)30732-7
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi:10.1016/s0140-6736(21)00588-2
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, Kawashima M. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two Phase III, long-term studies. Br J Dermatol. 2022;186(4):642–651. doi:10.1111/bjd.20873
   PubMed Web of Science ®Google Scholar
• Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: a systematic review. J Am Acad Dermatol. 2022;86(6):1318–1334. doi:10.1016/j.jaad.2021.04.077
   PubMed Web of Science ®Google Scholar
• Kołcz K, Żychowska M, Sawińska E, Reich A. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata. Dermatol Ther. 2023;13(3):843–856. doi:10.1007/s13555-023-00889-0
   PubMed Web of Science ®Google Scholar
• King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518–1529. doi:10.1016/s0140-6736(23)00222-2
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang W, Shi D. Tofacitinib treatment in a severe pediatric alopecia areata: a case report and a literature review. Skin Res Technol. 2024;30(1):e13553. doi:10.1111/srt.13553
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang Y, Xu M, Lyu Z, Wu X. Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: a Retrospective Cohort Study. Clin Cosmet Invest Dermatol. 2023;16:2947–2956. doi:10.2147/ccid.S425534
   PubMed Web of Science ®Google Scholar
• Youssef S, Bordone LA. Clinical response to oral tofacitinib in pediatric patients with alopecia areata. JAAD Case Rep. 2023;31:83–88. doi:10.1016/j.jdcr.2022.08.024
   PubMedGoogle Scholar
• Huang J, Li T, Tan Z, et al. Effectiveness of Tofacitinib in Pre-adolescent Alopecia Areata: a Retrospective Case Series and Literature Review. Acta Derm Venereol. 2023:103:adv13418. doi:10.2340/actadv.v103.13418
   Web of Science ®Google Scholar
• Wagh N. Tofacitinib: a Promising Treatment for Adolescent Alopecia Areata. Int J Trichol. 2023;15(3):113–114. doi:10.4103/ijt.ijt_90_23
   PubMedGoogle Scholar
• Geng SL, Gong T, Ji C, Su HH. Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children. J Eur Acad Dermatol Venereol. 2022;36(12):e1055–e1057. doi:10.1111/jdv.18447
   PubMed Web of Science ®Google Scholar
• Bhokare A. Recovery of Resistant Alopecia Areata Treated with Tofacitinib: an 8-Year-Old Child’s Case Report. Int J Trichol. 2022;14(4):135–137. doi:10.4103/ijt.ijt_15_22
   PubMedGoogle Scholar
• Moussa A, Eisman S, Kazmi A, et al. Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: a retrospective review of 29 patients. J Am Acad Dermatol. 2023;88(5):1194–1196. doi:10.1016/j.jaad.2022.12.033
   PubMed Web of Science ®Google Scholar
• Zhan J, Cao J, Chen F, Jin Y, Huang C. Real-data on the use of baricitinib in adolescents with severe alopecia areata. J Eur Acad Dermatol Venereol. 2023;17. doi:10.1111/jdv.19121
   Google Scholar
• Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib. Br J Dermatol. 2023;189(2):248–250. doi:10.1093/bjd/ljad118
   PubMed Web of Science ®Google Scholar
• Rotaru S, Common M, Mahé E. Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata. Ann Dermatol Venereol. 2023;150(2):160–161. doi:10.1016/j.annder.2023.02.001
   PubMed Web of Science ®Google Scholar
• Yu D, Ren Y. Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: a Case Report and Literature Review. Acta Derm Venereol. 2023;103:adv5578. doi:10.2340/actadv.v103.5578
   PubMed Web of Science ®Google Scholar
• Ha GU, Kim JH, Jang YH. Improvement of severe alopecia areata in an adolescent patient on upadacitinib. Pediatr Dermatol. 2023. doi:10.1111/pde.15504
   PubMed Web of Science ®Google Scholar
• Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report. SAGE Open Med Case Rep. 2022;10:2050313x221138452. doi:10.1177/2050313x221138452
   Web of Science ®Google Scholar
• Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. JAAD Case Rep. 2022;22:99–100. doi:10.1016/j.jdcr.2022.02.027
   PubMedGoogle Scholar
• Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib. J Cosmet Dermatol. 2024;23(1):348–349. doi:10.1111/jocd.15896
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi:10.1111/jdv.18345
   PubMed Web of Science ®Google Scholar